The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19’ is far from reality

{ 'indexed': {'date-parts': [[2023, 1, 8]], 'date-time': '2023-01-08T06:17:47Z', 'timestamp': 1673158667090}, 'reference-count': 39, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 1, 7]], 'date-time': '2023-01-07T00:00:00Z', 'timestamp': 1673049600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2023, 1, 7]], 'date-time': '2023-01-07T00:00:00Z', 'timestamp': 1673049600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The efficacy of Hydroxychloroquine (HCQ) as ' 'post-exposure prophylaxis (PEP) for the prevention of COVID-19 was contentious. In this ' 'randomized control double-blind clinical trial, asymptomatic individuals with direct contact ' 'with laboratory-confirmed COVID-19 cases were randomized into PEP/HCQ (N\u2009=\u2009574) and ' 'control/placebo (N\u2009=\u2009594) group. The PEP/HCQ group received tablet HCQ 400\xa0mg q ' '12 hourly on day one followed by 400\xa0mg once weekly for 3\xa0weeks, and the ' 'control/Placebo group received matching Placebo. The incidence of COVID-19 was similar ' '(p\u2009=\u20090.761) in PEP [N\u2009=\u200924 out of 574, (4.2%)] and control [N\u2009=\u2009' '27 out of 594, (4.5%)] groups. Total absolute risk reduction for the incidence of new-onset ' 'COVID-19 was -0.3% points with an overall relative risk of 0.91 (95% confidence interval, ' '0.52 to 1.60) and the number needed to treat (NNT) was 333 to prevent the incident of one ' 'case of COVID-19. The study found that, PEP with HCQ was not advantageous for the prevention ' 'of COVID-19 in asymptomatic individuals with high risk for SARS-CoV-2 infection. Though HCQ ' 'is\xa0a safer drug, the practice of irrational and indiscriminate use of HCQ for COVID-19 ' 'should be restrained with better pharmacovigilance.</jats:p>', 'DOI': '10.1038/s41598-022-26053-w', 'type': 'journal-article', 'created': {'date-parts': [[2023, 1, 7]], 'date-time': '2023-01-07T14:05:48Z', 'timestamp': 1673100348000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of ' 'COVID-19’ is far from reality', 'prefix': '10.1038', 'volume': '13', 'author': [ {'given': 'Deba Prasad', 'family': 'Dhibar', 'sequence': 'first', 'affiliation': []}, {'given': 'Navneet', 'family': 'Arora', 'sequence': 'additional', 'affiliation': []}, {'given': 'Deepak', 'family': 'Chaudhary', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ajay', 'family': 'Prakash', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bikash', 'family': 'Medhi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Neeraj', 'family': 'Singla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ritin', 'family': 'Mohindra', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vikas', 'family': 'Suri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ashish', 'family': 'Bhalla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Navneet', 'family': 'Sharma', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mini P.', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'P. V. M.', 'family': 'Lakshmi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kapil', 'family': 'Goyal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Arnab', 'family': 'Ghosh', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 1, 7]]}, 'reference': [ { 'key': '26053_CR1', 'unstructured': 'WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/'}, {'key': '26053_CR2', 'unstructured': 'COVID-19 Dashboard. https://www.mygov.in/covid-19/'}, { 'key': '26053_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'volume': '382', 'author': 'W Guan', 'year': '2020', 'unstructured': 'Guan, W. et al. Clinical Characteristics of coronavirus disease 2019 in ' 'China. N. Engl. J. Med. 382, 1708–20. ' 'https://doi.org/10.1056/NEJMoa2002032 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '26053_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1851', 'DOI': '10.1056/NEJMe2005477', 'volume': '382', 'author': 'LR Baden', 'year': '2020', 'unstructured': 'Baden, L. R. & Rubin, E. J. Covid-19: The search for effective therapy. ' 'N. Engl. J. Med. 382, 1851–1852. https://doi.org/10.1056/NEJMe2005477 ' '(2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '26053_CR5', 'doi-asserted-by': 'publisher', 'first-page': 'm3379', 'DOI': '10.1136/bmj.m3379', 'volume': '370', 'author': 'B Rochwerg', 'year': '2020', 'unstructured': 'Rochwerg, B. et al. A living WHO guideline on drugs for covid-19. BMJ ' '370, m3379. https://doi.org/10.1136/bmj.m3379 (2020).', 'journal-title': 'BMJ'}, { 'issue': '1', 'key': '26053_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.4103/ijp.IJP_119_20', 'volume': '52', 'author': 'P Sarma', 'year': '2020', 'unstructured': 'Sarma, P. et al. Therapeutic options for the treatment of 2019-novel ' 'coronavirus: An evidence-based approach. Indian J. Pharmacol. 52(1), 1–5 ' '(2020).', 'journal-title': 'Indian J. Pharmacol.'}, { 'key': '26053_CR7', 'doi-asserted-by': 'publisher', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'volume': '30', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang, M. et al. Remdesivir and chloroquine effectively inhibit the ' 'recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, ' '269–271. https://doi.org/10.1038/s41422-020-0282-0 (2020).', 'journal-title': 'Cell Res.'}, { 'key': '26053_CR8', 'doi-asserted-by': 'publisher', 'first-page': 'E68', 'DOI': '10.1016/S2213-2600(22)00192-8', 'volume': '10', 'author': 'T Burki', 'year': '2022', 'unstructured': 'Burki, T. The future of Paxlovid for COVID-19. Lancet Respir. Med. 10, ' 'E68. https://doi.org/10.1016/S2213-2600(22)00192-8 (2022).', 'journal-title': 'Lancet Respir. Med.'}, { 'key': '26053_CR9', 'doi-asserted-by': 'publisher', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'volume': '386', 'author': 'AJ Bernal', 'year': '2022', 'unstructured': 'Bernal, A. J. et al. Molnupiravir for oral treatment of Covid-19 in ' 'nonhospitalized patients. N. Engl. J. Med. 386, 509–20. ' 'https://doi.org/10.1056/NEJMoa2116044 (2022).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '26053_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'volume': '385', 'author': 'A Gupta', 'year': '2021', 'unstructured': 'Gupta, A. et al. Early treatment for covid-19 with SARS-CoV-2 ' 'neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–50. ' 'https://doi.org/10.1056/NEJMoa2107934 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '26053_CR11', 'unstructured': 'FDA Updates Sotrovimab Emergency Use Authorization. ' 'https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization.'}, { 'key': '26053_CR12', 'doi-asserted-by': 'publisher', 'author': 'P Gautret', 'year': '2020', 'unstructured': 'Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of ' 'COVID-19: Results of an open-label non-randomized clinical trial. Int. ' 'J. Antimicrob. Agents https://doi.org/10.1016/j.ijantimicag.2020.105949 ' '(2020).', 'journal-title': 'Int. J. Antimicrob. Agents', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': '26053_CR13', 'doi-asserted-by': 'publisher', 'first-page': '459', 'DOI': '10.4103/ijmr.IJMR_2234_20', 'volume': '151', 'author': 'P Chatterjee', 'year': '2020', 'unstructured': 'Chatterjee, P. et al. Healthcare workers & SARS-CoV-2 infection in ' 'India: A case-control investigation in the time of COVID-19. Indian J. ' 'Med. Res. 151, 459–467. https://doi.org/10.4103/ijmr.IJMR_2234_20 ' '(2020).', 'journal-title': 'Indian J. Med. Res.'}, { 'key': '26053_CR14', 'doi-asserted-by': 'publisher', 'first-page': '11974', 'DOI': '10.1038/s41598-021-91089-3', 'volume': '11', 'author': 'B Amani', 'year': '2021', 'unstructured': 'Amani, B., Khanijahani, A. & Amani, B. Hydroxychloroquine plus standard ' 'of care compared with standard of care alone in COVID-19: A ' 'meta-analysis of randomized controlled trials. Nat. Sci. Rep. 11, 11974. ' 'https://doi.org/10.1038/s41598-021-91089-3 (2021).', 'journal-title': 'Nat. Sci. Rep.'}, { 'key': '26053_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'CD013587', 'DOI': '10.1002/14651858.CD013587.pub2', 'volume': '2', 'author': 'B Singh', 'year': '2021', 'unstructured': 'Singh, B., Ryan, H., Kredo, T., Chaplin, M. & Fletcher, T. Chloroquine ' 'or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane ' 'Database Syst. Rev. 2, CD013587. ' 'https://doi.org/10.1002/14651858.CD013587.pub2 (2021).', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': '26053_CR16', 'unstructured': 'ICMR Recommendation for Empiric Use of Hydroxy-Chloroquine for ' 'Prophylaxis of SARS-CoV-2 Infection. ' 'https://www.icmr.gov.in/pdf/covid/techdoc/archive/HCQ_Recommendation_22March_final_MM_V2.pdf.'}, { 'key': '26053_CR17', 'unstructured': 'Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis ' 'for SARS-CoV-2 infection (in supersession of previous advisory dated ' '23rd March, 2020). ' 'https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf.'}, { 'key': '26053_CR18', 'doi-asserted-by': 'publisher', 'author': 'DP Dhibar', 'year': '2020', 'unstructured': 'Dhibar, D. P. et al. Post-exposure prophylaxis with hydroxychloroquine ' 'for the prevention of COVID-19, a myth or a reality? The PEP-CQ study. ' 'Int. J. Antimicrob. Agents ' 'https://doi.org/10.1016/j.ijantimicag.2020.106224 (2020).', 'journal-title': 'Int. J. Antimicrob. Agents', 'DOI': '10.1016/j.ijantimicag.2020.106224'}, { 'key': '26053_CR19', 'doi-asserted-by': 'publisher', 'first-page': '287', 'DOI': '10.7326/M20-2496', 'volume': '173', 'author': 'AV Hernandez', 'year': '2020', 'unstructured': 'Hernandez, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J. & White, ' 'C. M. Hydroxychloroquine or chloroquine for treatment or prophylaxis of ' 'COVID-19: A living systematic review. Ann. Intern. Med. 173, 287–296. ' 'https://doi.org/10.7326/M20-2496 (2020).', 'journal-title': 'Ann. Intern. Med.'}, { 'key': '26053_CR20', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0244778', 'volume': '16', 'author': 'K Lewis', 'year': '2021', 'unstructured': 'Lewis, K. et al. The efficacy and safety of hydroxychloroquine for ' 'COVID-19 prophylaxis: A systematic review and meta-analysis of ' 'randomized trials. PLoS ONE 16, e0244778 (2021).', 'journal-title': 'PLoS ONE'}, { 'key': '26053_CR21', 'doi-asserted-by': 'publisher', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'volume': '383', 'author': 'DR Boulware', 'year': '2020', 'unstructured': 'Boulware, D. R. et al. A randomized trial of hydroxychloroquine as ' 'postexposure prophylaxis for Covid-19. N. Engl. J. Med. 383, 517–525. ' 'https://doi.org/10.1056/NEJMoa2016638 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '26053_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1161', 'DOI': '10.1016/j.jiph.2021.08.001', 'volume': '14', 'author': 'RB Stricker', 'year': '2021', 'unstructured': 'Stricker, R. B. & Fesler, M. C. Hydroxychloroquine pre-exposure ' 'prophylaxis for COVID-19 in healthcare workers from India: A ' 'meta-analysis. J. Infect. Public Health 14, 1161–1163 (2021).', 'journal-title': 'J. Infect. Public Health'}, { 'issue': '6', 'key': '26053_CR23', 'doi-asserted-by': 'publisher', 'first-page': '333', 'DOI': '10.33696/immunology.2.063', 'volume': '2', 'author': 'A Yang', 'year': '2020', 'unstructured': 'Yang, A., Guduguntla, L. S. & Yang, B. Potentials of interferons and ' 'hydroxychloroquine for the prophylaxis and early treatment of COVID-19. ' 'J. Cell Immunol. 2(6), 333–340. ' 'https://doi.org/10.33696/immunology.2.063 (2020).', 'journal-title': 'J. Cell Immunol.'}, { 'key': '26053_CR24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tmaid.2020.101738', 'volume': '35', 'author': 'M Million', 'year': '2020', 'unstructured': 'Million, M. et al. Early treatment of COVID-19 patients with ' 'hydroxychloroquine and azithromycin: A retrospective analysis of 1061 ' 'cases in Marseille, France. Travel Med. Infect. Dis. 35, 101738. ' 'https://doi.org/10.1016/j.tmaid.2020.101738 (2020).', 'journal-title': 'Travel Med. Infect. Dis.'}, { 'key': '26053_CR25', 'doi-asserted-by': 'publisher', 'first-page': '106144', 'DOI': '10.1016/j.ijantimicag.2020.106144', 'volume': '56', 'author': 'L Catteau', 'year': '2020', 'unstructured': 'Catteau, L. et al. Low-dose hydroxychloroquine therapy and mortality in ' 'hospitalized patients with COVID-19: A nationwide observational study of ' '8075 participants. Int J. Antimicrob. Agents 56, 106144. ' 'https://doi.org/10.1016/j.ijantimicag.2020.106144 (2020).', 'journal-title': 'Int J. Antimicrob. Agents'}, { 'key': '26053_CR26', 'doi-asserted-by': 'publisher', 'first-page': '276', 'DOI': '10.1038/s41586-021-03777-9', 'volume': '596', 'author': 'D Planas', 'year': '2021', 'unstructured': 'Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to ' 'antibody neutralization. Nature 596, 276–280 (2021).', 'journal-title': 'Nature'}, { 'key': '26053_CR27', 'first-page': '1', 'volume': '28', 'author': 'NC Kyriakidis', 'year': '2021', 'unstructured': 'Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B. & ' 'Prado, E. O. SARS-CoV-2 vaccines strategies: A comprehensive review of ' 'phase 3 candidates. NPJ Vaccines 28, 1–17 (2021).', 'journal-title': 'NPJ Vaccines'}, { 'key': '26053_CR28', 'doi-asserted-by': 'publisher', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'volume': '71', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao, X. et al. In vitro antiviral activity and projection of optimized ' 'dosing design of hydroxychloroquine for the treatment of severe acute ' 'respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, ' '732–739. https://doi.org/10.1093/cid/ciaa237 (2020).', 'journal-title': 'Clin. Infect. Dis.'}, { 'key': '26053_CR29', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2020.111138', 'volume': '135', 'author': 'BB Bazotte', 'year': '2021', 'unstructured': 'Bazotte, B. B. et al. 4-Aminoquinoline compounds from the Spanish flu to ' 'COVID-19. Biomed. Pharmacother. 135, 111138 (2021).', 'journal-title': 'Biomed. Pharmacother.'}, { 'key': '26053_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1213', 'DOI': '10.2147/DDDT.S293216', 'volume': '15', 'author': 'Y Yang', 'year': '2021', 'unstructured': 'Yang, Y., Cui, X., Wei, H., Guo, C. & Zhang, Y. Potential ' 'anti-coronavirus agents and the pharmacologic mechanisms. Drug Des. Dev. ' 'Ther. 15, 1213–1223 (2021).', 'journal-title': 'Drug Des. Dev. Ther.'}, { 'key': '26053_CR31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.biopha.2020.111008', 'volume': '133', 'author': 'BM Bakadia', 'year': '2021', 'unstructured': 'Bakadia, B. M. et al. Prevention and treatment of COVID-19: Focus on ' 'interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. ' 'Biomed. Pharmacother. 133, 111008 (2021).', 'journal-title': 'Biomed. Pharmacother.'}, { 'key': '26053_CR32', 'doi-asserted-by': 'publisher', 'first-page': '344', 'DOI': '10.7326/M20-6519', 'volume': '174', 'author': 'RV Barnabas', 'year': '2021', 'unstructured': 'Barnabas, R. V. et al. Hydroxychloroquine as postexposure prophylaxis to ' 'prevent severe acute respiratory syndrome coronavirus 2 infection: A ' 'randomized trial. Ann. Intern. Med. 174, 344–52. ' 'https://doi.org/10.7326/M20-6519 (2021).', 'journal-title': 'Ann. Intern. Med.'}, { 'key': '26053_CR33', 'doi-asserted-by': 'publisher', 'first-page': '417', 'DOI': '10.1056/NEJMoa2021801', 'volume': '384', 'author': 'O Mitjà', 'year': '2021', 'unstructured': 'Mitjà, O. et al. A cluster-randomized trial of hydroxychloroquine for ' 'prevention of Covid-19. N. Engl. J. Med. 384, 417–27 (2021).', 'journal-title': 'N. Engl. J. Med.'}, { 'issue': '2', 'key': '26053_CR34', 'doi-asserted-by': 'publisher', 'first-page': '195', 'DOI': '10.1001/jamainternmed.2020.6319', 'volume': '181', 'author': 'BS Abella', 'year': '2021', 'unstructured': 'Abella, B. S. et al. Efficacy and safety of hydroxychloroquine vs ' 'placebo for pre-exposure SARS-CoV-2 prophylaxis among health care ' 'workers. A randomized clinical trial. JAMA Intern. Med. 181(2), 195–202. ' 'https://doi.org/10.1001/jamainternmed.2020.6319 (2021).', 'journal-title': 'JAMA Intern. Med.'}, { 'key': '26053_CR35', 'doi-asserted-by': 'publisher', 'first-page': 'e835', 'DOI': '10.1093/cid/ciaa1571', 'volume': '72', 'author': 'R Rajasingham', 'year': '2021', 'unstructured': 'Rajasingham, R. et al. Hydroxychloroquine as pre-exposure prophylaxis ' 'for coronavirus disease 2019 (COVID-19) in healthcare workers: A ' 'randomized trial. CID 72, e835–e843 (2021).', 'journal-title': 'CID'}, { 'key': '26053_CR36', 'doi-asserted-by': 'publisher', 'first-page': '1386', 'DOI': '10.1016/j.ophtha.2016.01.058', 'volume': '123', 'author': 'MF Marmor', 'year': '2016', 'unstructured': 'Marmor, M. F. et al. Recommendations on screening for chloroquine and ' 'hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123, ' '1386–94. https://doi.org/10.1016/j.ophtha.2016.01.058 (2016).', 'journal-title': 'Ophthalmology'}, { 'key': '26053_CR37', 'doi-asserted-by': 'publisher', 'first-page': '776', 'DOI': '10.1002/jmv.25898', 'volume': '92', 'author': 'P Sarma', 'year': '2020', 'unstructured': 'Sarma, P. et al. Virological and clinical cure in COVID-19 patients ' 'treated with hydroxychloroquine: A systematic review and meta-analysis. ' 'J. Med. Virol. 92, 776–785. https://doi.org/10.1002/jmv.25898 (2020).', 'journal-title': 'J. Med. Virol.'}, { 'key': '26053_CR38', 'unstructured': 'The National Task Force on COVID-19. ' 'https://www.icmr.gov.in/pdf/covid/techdoc/Considerations_for_Exclusion_of_IVM_and_HCQ.pdf.'}, { 'key': '26053_CR39', 'doi-asserted-by': 'publisher', 'first-page': '1973', 'DOI': '10.1016/S0140-6736(20)31142-9', 'volume': '395', 'author': 'DK Chu', 'year': '2020', 'unstructured': 'Chu, D. K. et al. Physical distancing, face masks and eye protection to ' 'prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A ' 'systematic review and meta-analysis. Lancet. 395, 1973–87 (2020).', 'journal-title': 'Lancet.'}], 'container-title': 'Scientific Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41598-022-26053-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-26053-w', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41598-022-26053-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 1, 7]], 'date-time': '2023-01-07T14:08:45Z', 'timestamp': 1673100525000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41598-022-26053-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 7]]}, 'references-count': 39, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 12]]}}, 'alternative-id': ['26053'], 'URL': 'http://dx.doi.org/10.1038/s41598-022-26053-w', 'relation': {}, 'ISSN': ['2045-2322'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Sci Rep', 'published': {'date-parts': [[2023, 1, 7]]}, 'assertion': [ { 'value': '25 March 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '8 December 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 January 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '378'}